Salameh T, Mortell W, Logsdon A, Butterfield D, Banks W. Disruption of the hippocampal and hypothalamic blood-brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate. Fluids Barriers CNS. 2019;16:1 pubmed publisher

Royal P, Andres Bilbe A, Ávalos Prado P, Verkest C, Wdziekonski B, Schaub S, et al. Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK. Neuron. 2019;101:232-245.e6 pubmed publisher

Liu Y, Wang X, Li D, Yang L, Huang S. Short-term use of antiepileptic drugs is neurotoxic to the immature brain. Neural Regen Res. 2015;10:599-604 pubmed publisher

Patrick P, Price T, Diogo A, Sheibani N, Banks W, Shah G. Topiramate Protects Pericytes from Glucotoxicity: Role for Mitochondrial CA VA in Cerebromicrovascular Disease in Diabetes. J Endocrinol Diabetes. 2015;2: pubmed

Kaneko Y, Sullivan R, Dailey T, Vale F, Tajiri N, Borlongan C. Kainic Acid-Induced Golgi Complex Fragmentation/Dispersal Shifts the Proteolysis of Reelin in Primary Rat Neuronal Cells: An In Vitro Model of Early Stage Epilepsy. Mol Neurobiol. 2016;53:1874-1883 pubmed publisher

Harshman H, Kovach F. Clinical inquiries: is immediate-release topiramate an effective treatment for adult obesity?. J Fam Pract. 2014;63:745-6 pubmed

. In brief: topiramate extended-release capsules (Qudexy XR). Med Lett Drugs Ther. 2014;56:e126 pubmed

Chung S, Fakhoury T, Hogan R, Nagaraddi V, Blatt I, Lawson B, et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia. 2014;55:1077-87 pubmed publisher

Clark A, Halvorsen M, Braun T, Johnson K, Cloyd J. USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers. Epilepsia. 2014;55:1069-76 pubmed publisher

Jonas D, Amick H, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889-900 pubmed publisher

Batki S, Pennington D. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014;171:391-4 pubmed publisher

Xiong G, Gadde K. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med. 2014;126:110-6 pubmed publisher

Kranzler H, Covault J, Feinn R, Armeli S, Tennen H, Arias A, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171:445-52 pubmed publisher

Woloshin S, Schwartz L. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?. JAMA Intern Med. 2014;174:615-9 pubmed publisher

Crockett S, Schectman R, STURMER T, Kappelman M. Topiramate use does not reduce flares of inflammatory bowel disease. Dig Dis Sci. 2014;59:1535-43 pubmed publisher

Cárdenas Rodríguez N, Coballase Urrutia E, Rivera Espinosa L, Romero Toledo A, Sampieri A, Ortega Cuellar D, et al. Modulation of antioxidant enzymatic activities by certain antiepileptic drugs (valproic acid, oxcarbazepine, and topiramate): evidence in humans and experimental models. Oxid Med Cell Longev. 2013;2013:598493 pubmed publisher

Bonnett L, Tudur Smith C, Smith D, Williamson P, Chadwick D, Marson A. Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. J Neurol Neurosurg Psychiatry. 2014;85:603-10 pubmed publisher

Kraft P, Müllges W. Musical murmurs on transcranial ultrasound in childhood migraine with aura. Neurology. 2013;81:1880 pubmed publisher

. Topiramate extended-release (Trokendi XR) for epilepsy. Med Lett Drugs Ther. 2013;55:87-8 pubmed

Johnson B, Ait Daoud N, Wang X, Penberthy J, Javors M, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70:1338-46 pubmed publisher

Baretić M. Obesity drug therapy. Minerva Endocrinol. 2013;38:245-54 pubmed

Shah G, Morofuji Y, Banks W, Price T. High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: Implications for cerebral microvascular disease in diabetes. Biochem Biophys Res Commun. 2013;440:354-8 pubmed publisher

Kelly E, Tungol A, Wesolowicz L. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. J Manag Care Pharm. 2013;19:642-54 pubmed

Liu Y, Rhee D. Acute bilateral angle closure. JAMA Ophthalmol. 2013;131:1231-2 pubmed publisher

Wiffen P, Derry S, Lunn M, Moore R. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;:CD008314 pubmed publisher

Borron S, Woolard R, Watts S. Fatal heat stroke associated with topiramate therapy. Am J Emerg Med. 2013;31:1720.e5-6 pubmed publisher

Kim D, Lee S, Shon Y, Kim J. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia. 2013;54:e146-9 pubmed publisher

Fleming J, McClendon K, Riche D. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother. 2013;47:1007-16 pubmed publisher

Linde M, Mulleners W, Chronicle E, McCrory D. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;:CD010610 pubmed publisher

Garvey W. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013;12:741-56 pubmed publisher

Halpern B, Faria A, Halpern A. Fixed-dose combination of phentermine-topiramate for the treatment of obesity. Expert Rev Clin Pharmacol. 2013;6:235-41 pubmed publisher

Cosentino G, Conrad A, Uwaifo G. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013;7:267-78 pubmed publisher

Sonmez F, Serin H, Alver A, Aliyazicioglu R, Cansu A, Can G, et al. Blood levels of cytokines in children with idiopathic partial and generalized epilepsy. Seizure. 2013;22:517-21 pubmed publisher

Katsi V, Marketou M, Kallistratos M, Tousoulis D, Makris T, Manolis A, et al. Phentermine and topiramate extended-release for the obesity: new kids on the block. Recent Pat Cardiovasc Drug Discov. 2013;8:35-41 pubmed

Sierra Hidalgo F, de Pablo Fernández E. Palinopsia induced by topiramate and zonisamide in a patient with migraine. Clin Neuropharmacol. 2013;36:63-4 pubmed publisher

Smith S, Meyer M, Trinkley K. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47:340-9 pubmed

Hahn M, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses. 2013;6:186-96 pubmed publisher

Mahmood S, Booker I, Huang J, Coleman C. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013;33:90-4 pubmed publisher

Chen L, Feng P, Li Y, Zhou D. Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model. J Mol Neurosci. 2013;51:1-8 pubmed publisher

Abtahi S, Abtahi M, Etemadifar M, Mazloumi M, Attarzadeh H. Effects of Topiramate on afferent visual pathways: controversies and uncertainties. Neurol Sci. 2013;34:603-4 pubmed publisher

Siniscalchi A, Gallelli L, Giofrè C, De Sarro G. What's the role of topiramate in the management of patients with hyperkinetic movement disorders?. Pharmacol Rep. 2012;64:24-30 pubmed

Bays H, Gadde K. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc). 2011;47:903-14 pubmed publisher

Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol. 2012;:433-66 pubmed publisher

Price T, Eranki V, Banks W, Ercal N, Shah G. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology. 2012;153:362-72 pubmed publisher

Wang Q, Bai M. Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia: a meta-analysis. CNS Drugs. 2011;25:847-57 pubmed publisher

Ferrari A, Tiraferri I, Neri L, Sternieri E. Clinical pharmacology of topiramate in migraine prevention. Expert Opin Drug Metab Toxicol. 2011;7:1169-81 pubmed publisher

Sreekumar A, Poisson L, Rajendiran T, Khan A, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4 pubmed publisher

Navarro J, Buron E, Martin Lopez M. Antiaggressive effects of topiramate in agonistic encounters between male mice. Methods Find Exp Clin Pharmacol. 2007;29:195-8 pubmed

Brandes J, Saper J, Diamond M, Couch J, Lewis D, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965-73 pubmed

Gryder D, Rogawski M. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003;23:7069-74 pubmed

Johnson B, Ait Daoud N, Bowden C, DiClemente C, Roache J, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-85 pubmed

Smith Swintosky V, Zhao B, Shank R, Plata Salaman C. Topiramate promotes neurite outgrowth and recovery of function after nerve injury. Neuroreport. 2001;12:1031-4 pubmed

Shank R, Gardocki J, Streeter A, Maryanoff B. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3-9 pubmed

Riffitts J, Gisclon L, Stubbs R, Palmer M. A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. J Pharm Biomed Anal. 1999;19:363-71 pubmed

Petroff O, Hyder F, Mattson R, Rothman D. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52:473-8 pubmed